Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Sandercock, Peter A G ^a   Counsell, Carl ^b   Tseng, Mei Chiun ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Anticoagulants *therapeutic use ; Brain ischemia drug therapy ; Fibrinolytic agents *therapeutic use ; Heparin therapeutic use ; Heparin, low molecular weight *therapeutic use ; Heparinoids *therapeutic use

Indexed keywords

CERTOPARIN; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MESOGLYCAN; NADROPARIN; PARNAPARIN; PENTOSAN POLYSULFATE; REVIPARIN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARINOID;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DEATH; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; FUNCTIONAL ASSESSMENT; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; BRAIN ISCHEMIA; RANDOMIZED CONTROLLED TRIAL; STROKE;

ANTICOAGULANTS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARINOIDS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 55049139942     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000119.pub3     Document Type: Review

References (54)

1. Dumas 1994 {published and unpublished data} Dumas R, Woitinas F, Kutnowski M, Nikolic I, Berberich R, Abedinpour F, et al.A multi-centre double blind randomized study to compare the safety and efficacy of once-daily ORG10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age and Ageing 1994;23:512-6.
2. Hageluken C, Egberts J, Stiekema J. A multi-centre, assessor-blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non-haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands 1992.
3. Hageluken 1992 {unpublished data only} Hageluken C, Egberts J. A multi-centre, assessor-blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non-haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands 1992.
4. Hillbom 1998 {published and unpublished data} Hillbom M, Erila T, Flosbach C, Sotaniemi K, Tatlisumak T, Sarna S, et al.Enoxaparin, a low-molecular-weight heparin (LWMH) may be superior to standard heparin in the prevention of deep-vein thrombosis (DVT) in stroke patients. European Journal of Neurology 1998;5 Suppl 3:S110.
5. Hillbom M, Erila T, Flosbach CW, Sotaniemi K, Sarna S, Kaste M. Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke. Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14-21; Washington, DC, USA. 1999.
6. Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. Blood 1999;94 Suppl 1:183a.
7. * Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurologica Scandinavica 2002;106:84-92.
8. PREVAIL 2007 {published data only} Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, et al.The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007;369:1347-55.
9. PROTECT 2006 {published data only} Diener H-C, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J, et al.Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin. Results of the PROTECT Trial. Stroke 2006;37:139-44.
10. Stiekema 1988 {published and unpublished data} Hossman V, Loettgen J, Auel H, Bewermeyer H, Heiss WD. Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double-blind study. Haemostasis 1986;16 Suppl 5:54.
11. Stiekema JCJ, Egberts JFM, Voerman J. An open, randomised, pilot multi-centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non-haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands 1988.
12. TRACE 2004 {published data only} Woessner R, Grauer M, Bianchi O, Mueller M, Moersdorf S, Berlit P, et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis 2004;91:690-3.
13. Turpie 1992 {published and unpublished data} Magnani HN, Egberts JFM. A preliminary report of a multi-centre, assessor-blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004-010). Organon International B.V (Internal report SDGRR No. 3172). Oss, the Netherlands 1992.
14. Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992;22:92-8.
15. Turpie AGG, Levine MN, Powers PJ, Ginsberg JG, Jay RM, Klimek M, et al.A double blind randomized trial of Org 10172 Low Molecular Weight Heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis 1991;65:753.
16. * Turpie AGG, Levine MN, Powers PJ, Ginsberg JG, Jay RM, Klimek M, et al.A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine 1992;117:353-7.
17. Wong 2000 {published and unpublished data} Wong W-J, Lo Y-K, Hu H-H. Comparison of subcutaneous lowmolecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases 2000;9 Suppl 1:183-4.
18. EMSG 1996 {published data only} Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thrombosis and Haemostasis 1996;76:529-34.
19. EUROTOAST 1996 {published data only (unpublished sought but not used)} Egberts JFM, Sommer W. Multicentre, randomised, assessor-blind, dose-comparative study of Org 10172 (Orgaran) in the treatment of acute ischaemic stroke. Personal communication 1996.
20. Harenberg 1999 {published data only} Harenberg J, Schomaker U, Floshbach CW. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk. Blood 1999;94 Suppl 10:399a.
21. HESIM 1990 {published data only} Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, et al.Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thrombosis Research 1990;59:639- 50.
22. Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL, et al.Heparin study in internalmedicine (HESIM): design and preliminary results. Thrombosis Research 1992;68:33-43.
23. McCarthy 1993 {unpublished data only} McCarthy S, McWalter R, Durkin CJ, Hallawi AH. Org 10172 for the prophylaxis of deep venous thrombosis in the legs. A protocol to establish the efficacy and safety of once or twice daily subcutaneous Org 10172 injections vs placebo in 3 groups of 60 non-haemorrhagic stroke victims. Unpublished protocol.
24. Moulin 1994 {unpublished data only} Crepin-Leblond T, Moulin T, Ziegler F, Bataillard M, Chopard L, Chavot D, et al.A randomised trial of heparin therapy in acute ischemic stroke: first results. Cerebrovascular Diseases 1994;4:259.
25. Nikc Evic 2006 {published data only} Nikc Evic LD, Savic MB, Plavsic AT, Hrkovic MK. Applying of LMWH (clexane) and results of early rehabilitation in patients after ischemic stroke. International Journal of Stroke 2006;1 Suppl 1:153.
26. Szirmai 1986 {unpublished data only} Szirmai I, Fendler K, Koller L. Clinical experience with heparinoid sodium pentosan polysulphate (SP54) in treatment of cerebral ischaemia. Folia Haematologia Leipzig 1986;113:278-88.
27. Aventis 2002 {unpublished data only} Aventis Pharma. An open-label, randomised, parallel-group, multicentre study to evaluate the efficacy and safety of enoxaparin versus unfractionated heparin in the prevention of venous thromboembolism in patients following acute ischaemic stroke. Unpublished.
28. Young 2001 {unpublished data only} Young WD, Smythe LG. Low-molecular-weight heparin (enoxaparin) in anticoagulation transition to oral warfarin in ischaemic cerebral vascular accident (CVA) or transient ischaemic attack (TIA) patients. ASHP Midyear Clinical Meeting. 2001; Vol. 36: 496E.
29. ATC 1994 Antiplatelet Trialists' Collaboration. Collaborative overview of trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
30. Bath 2000 Bath P, Iddenden R, Bath F. Low-molecular weight heparins and heparinoids in acute ischemic stroke. Stroke 2000;31:1770-8.
31. CAST 1997 CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9.
32. Cella 1986 Cella G, Scattolo N, Luzzato G, Stevanato F, Vio C, Girolami A. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf. Journal of Medicine 1986;17:331-46.
33. Choay 1989 Choay J. Structure and activity of heparin and its fragments: an overview. Seminars in Thrombosis and Hemostasis 1989;15:359-64.
34. FISS-bis 1998 Hommel M. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases 1998;8:19.
35. Gordon 1990 Gordon DL, Linhardt R, Adams HP. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clinical Neuropharmacology 1990;13:522-43.
36. Gubitz 2004 Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2]
37. IST 1997 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
38. Koch 1997 Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention - update of previous meta-analyses. British Journal of Surgery 1997;84:750-9.
39. Kunz 2007 Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.MR000012.pub2.]
40. Leizorowicz 1992 Leizorovicz A, Haugh MC, Chapuis F-R, Samana MM, Boissel J-P. Low molecular weight heparins in the prevention of perioperative thrombosis. BMJ 1992;305:913-20.
41. Lowe 2003 Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?. Lancet 2003;362:504-5.
42. Macleod 2005 Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004898.pub2]
43. Maffrand 1991 Maffrand J-P, Herbert J-M, Bernat A, Defreyn G, Delebassee D, Savi P, et al.Experimental and clinical pharmacology of pentosan polysulphate. Seminars in Thrombosis and Hemostasis 1991;17 Suppl 2:186-98.
44. MEDSTRATEGY 1995 Dick E. Stroke: A focus of opportunity. St Louis, USA: MedStrategy, 1995.
45. Meuleman 1992 Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992;22:58-65.
46. Nurmohamed 1992 Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al.Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
47. Sandercock 1993 Sandercock PAG, van den Belt A, Lindley R, Slattery J. Antithrombotic therapy in acute stroke: an overview of the randomised trials. Journal of Neurology Neurosurgery & Psychiatry 1993;56:17-25.
48. Sandercock 2003a Sandercock P, Mielke O, Liu M, Counsell C. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD000248]
49. Sandercock 2003b Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000029]
50. Shorr 2008 Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a meta-analysis. Chest 2008;133:149-55.
51. TOAST 1998 Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 10172 (Danaparoid) and outcome after acute ischemic stroke. JAMA 1998;279:1265-72.
52. van Dongen 2004 van Dongen CJJ, van den Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858. CD001100.pub2]
53. Counsell 2001 Counsell C, Sandercock P. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2001, Issue 4. [Art. No.: CD000119. DOI: 10.1002/14651858.CD000119]
54. Sandercock 2005 Sandercock P, Counsell C, Stobbs SL. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2005, Issue 2. [Art. No.: CD000119. DOI: 10.1002/14651858.CD000119. pub2]